Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.7K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.7K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Catatonia during stroke rehabilitation: autoimmune encephalitis following meningovascular neurosyphilis.

Practical neurology·2026
Same author

ALS untangled #83: clenbuterol.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

ALSUntangled #82: N-acetylcysteine.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Toward a "green" brain health agenda: establishing short- and long-term goals for the field of neurology in a changing climate.

Frontiers in neurology·2026
Same author

ALSUntangled #81: Pyridostigmine (mestinon<sup>®</sup>).

Amyotrophic lateral sclerosis & frontotemporal degeneration·2025
Same author

Examining IGFBP7 as a potential therapeutic target in people with ALS.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2025

Related Experiment Video

Updated: Dec 14, 2025

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis
09:36

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis

Published on: June 23, 2022

3.8K

Total serum immunoglobulin A in ALS.

Jesse Crayle1, Mai Elmallah2, John Sleasman2

  • 1School of Medicine, Duke University, Durham, NC, USA.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|July 17, 2020
PubMed
Summary

This study investigated if immunoglobulin A (IgA) levels could explain the varied clinical presentations of amyotrophic lateral sclerosis (ALS). Researchers found no significant association between IgA levels and ALS variability, suggesting IgA is not a reliable biomarker.

Keywords:
Biomarkeramyotrophic lateral sclerosisimmunoglobulin A

More Related Videos

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.6K
Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
05:45

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

24.0K

Related Experiment Videos

Last Updated: Dec 14, 2025

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis
09:36

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis

Published on: June 23, 2022

3.8K
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.6K
Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
05:45

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

24.0K

Area of Science:

  • Neurology
  • Immunology
  • Biomarker Discovery

Background:

  • Amyotrophic lateral sclerosis (ALS) exhibits significant phenotypic variability.
  • Currently, no established biomarker effectively explains this clinical heterogeneity.
  • Investigating serum immunoglobulin A (IgA) levels offers a potential avenue to understand ALS variability.

Purpose of the Study:

  • To test the hypothesis that immunoglobulin A (IgA) serum concentrations correlate with the phenotypic variability observed in amyotrophic lateral sclerosis (ALS).
  • To determine if IgA levels can serve as a biomarker for different clinical presentations of ALS.

Main Methods:

  • Retrospective analysis of electronic health records from a tertiary academic medical center.
  • Inclusion of patients with ALS-spectrum disease (n=489), other neurodegenerative diseases (n=174), autoimmune neurologic diseases (n=154), and healthy controls (n=17475).
  • Statistical analysis controlling for age and sex to assess the association between total serum IgA concentrations and ALS clinical features.

Main Results:

  • No significant association was found between amyotrophic lateral sclerosis (ALS) and total serum immunoglobulin A (IgA) concentrations after adjusting for age and sex.
  • Extremes in serum IgA levels did not correlate with various clinical characteristics of ALS patients.
  • This large-scale study indicates that total serum IgA is not a significant predictor of ALS variability.

Conclusions:

  • The study provides robust evidence that total serum immunoglobulin A (IgA) concentration is not associated with the phenotypic variability in amyotrophic lateral sclerosis (ALS).
  • Serum IgA levels cannot be utilized as a standalone biomarker for predicting or explaining clinical differences in ALS.
  • Further research is needed to identify reliable biomarkers for ALS heterogeneity.